MiMedx Group Inc (NASDAQ:MDXG) : The consensus on MiMedx Group Inc (NASDAQ:MDXG) based on 6 analyst recommendation on the company stock is 1.33, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 5 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
MiMedx Group Inc (NASDAQ:MDXG) : The most positive equity analysts on MiMedx Group Inc (NASDAQ:MDXG) expects the shares to touch $13, whereas, the least positive believes that the stock will trade at $9 in the short term. The company is covered by 6 Wall Street Brokerage Firms. The average price target for shares are $11.5 with an expected fluctuation of $1.38 from the mean.
For the current week, the company shares have a recommendation consensus of Buy. Also, Equity Analysts at the Brokerage Firm, Lake Street, maintains their rating on the shares of MiMedx Group Inc (NASDAQ:MDXG). Lake Street has a Buy rating on the shares. As per the latest research report, the brokerage house lowers the price target to $12 per share from a prior target of $15. The rating by the firm was issued on April 19, 2016.
MiMedx Group Inc (NASDAQ:MDXG): stock turned positive on Tuesday. Though the stock opened at $7.25, the bulls momentum made the stock top out at $7.71 level for the day. The stock recorded a low of $7.235 and closed the trading day at $7.69, in the green by 8.16%. The total traded volume for the day was 1,290,990. The stock had closed at $7.11 in the previous days trading.
In an insider trading activity, The Securities and Exchange Commission has divulged that Taylor William Charles, director officer (President and COO) of Mimedx Group, Inc., had unloaded 24,333 shares at an average price of $7.52 in a transaction dated on June 16, 2016. The total value of the transaction was worth $182,984.
MiMedx Group, Inc. (MiMedx) is an integrated developer, manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Companys biomaterial platform technologies include AmnioFix and EpiFix, its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program, mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant, which is referred as an allograft. MiMedx is the supplier of amniotic tissue, having supplied over 350,000 allografts for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.